CJC-1295 without DAC — commonly called Mod GRF 1-29 — is a synthetic, truncated (1-29) growth hormone-releasing hormone (GHRH) analog. Unlike the DAC variant, it does not carry the albumin-binding Drug Affinity Complex, so its effective half-life is measured in minutes rather than days.

GH and IGF-1 elevation, sustained GHRH receptor agonism, body composition support, recovery enhancement, GH axis restoration.

Research on CJC-1295 (without DAC) primarily documents effects related to GH and IGF-1 elevation and sustained GHRH receptor agonism and body composition support and recovery enhancement and GH axis restoration. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for CJC-1295 (without DAC) include Active malignancy — caution (GH/IGF-1 is mitogenic), Pregnancy — caution, Known hypersensitivity. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.

For CJC-1295 (without DAC), its FDA status is Nomination Withdrawn, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

368 providers in the directory currently offer CJC-1295 (without DAC).

Across 44 research vendors tracked on PeptideBase, CJC-1295 (without DAC) has a median price of about $8.98 per mg, typically ranging $5.40–$13.00 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

# Summary of CJC-1295 Research Finding Research found that CJC-1295, classified as a growth hormone axis secretagogue, remains investigational with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions in the context of sports medicine applications. This study demonstrated that injectable peptides in this functional class lack the reproducible clinical evidence supporting other peptide categories and are not currently established as clinically adopted treatments for musculoskeletal recovery or tissue repair.

CJC-1295 (without DAC) is featured in the following research stacks on PeptideBase: CJC-1295 + Ipamorelin + BPC-157: Recovery & GH, CJC-1295 + Ipamorelin + GHRP-6: GH Secretagogue Max, CJC-1295 + Ipamorelin: GH Optimization.